Compare NEXR & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXR | LABT |
|---|---|---|
| Founded | N/A | N/A |
| Country | Israel | United States |
| Employees | 38 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.6M |
| IPO Year | 2022 | N/A |
| Metric | NEXR | LABT |
|---|---|---|
| Price | $0.47 | $2.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 18.1M | 276.0K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $2.10 |
| 52 Week High | $1.28 | $4.72 |
| Indicator | NEXR | LABT |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 31.54 |
| Support Level | N/A | $2.10 |
| Resistance Level | $1.28 | N/A |
| Average True Range (ATR) | 0.14 | 0.61 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 3.33 | 19.85 |
Nexera Technologies Ltd focuses on homeland security technologies, artificial intelligence-driven solutions, and detection systems through its subsidiaries and strategic collaborations. The company collaborates with technology partners to distribute and promote new systems such as 3D imaging and electromagnetic threat detection tools, autonomous security technologies, and multi-layered security ecosystems for critical infrastructure and high-traffic venues.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.